Bharat Biotech completes phase 3 trial of intranasal COVID vaccine

Bharat Biotech on Monday said it has completed clinical development for phase 3 trials and booster doses for the BBV154 (Covaxin) intranasal COVID-19 vaccine. Bharat Biotech International Limited announced that BBV154 has proven to be safe, well-tolerated and immunogenic in subjects in controlled clinical trials. It has been specifically formulated to allow intranasal delivery.